News|Videos|September 17, 2026
Episode 2: Taking Stock of Systemic and Local Therapy Trends in Lung Cancer With Drs Crowley and Moghanaki
Fionnuala Crowley, MD, Tisch Cancer Institute, and Drew Moghanaki, MD, MPH, FASTRO, UCLA Jonsson Comprehensive Cancer Center, sit down with Eric K. Singhi, MD, of The University of Texas MD Anderson Cancer Center, and Misty D. Shields, MD, PhD, of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer.
Advertisement
Fionnuala Crowley, MD, Tisch Cancer Institute, and Drew Moghanaki, MD, MPH, FASTRO, UCLA Jonsson Comprehensive Cancer Center, sit down with Eric K. Singhi, MD, of The University of Texas MD Anderson Cancer Center, and Misty D. Shields, MD, PhD, of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer.
Advertisement
Related to this article
The FDA has approved taletrectinib (Ibtrozi) for use in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.
Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.
A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
European Approval Is Sought for Lirafugratinib in FGFR2-Altered Metastatic Cholangiocarcinoma
2
FDA Approves Taletrectinib for Locally Advanced or Metastatic ROS1+ NSCLC
3
TUB-040 Elicits Clinically Meaningful Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer
4
PET-Guided Nivolumab Yields High Responses in Hodgkin Lymphoma
5